Navigation Links
ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Date:4/23/2009

For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral inducer of endogenous interferons that acts via the TLR7 pathway. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to (i) the potency, safety and tolerability profile of ANA598, which may not be duplicated in future cohorts at higher doses or future clinical studies of longer duration; (ii) the belief that ANA598 is a leading non-nucleoside polymerase inhibitor in development for the treatment of HCV; (iii) the expectation that ANA598 will be active in long-term studies in combination with pegylated interferon and ribavirin and the ability to dose ANA598 for up to 48 weeks in future combination studies; (iv) the ability of Anadys to transition into Phase II studies of ANA598 during 2009; and (v) expectations regarding the evolution of the market for HCV therapies. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies (including those described in this press release) may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 will not have unforeseen safety issues, will have favorable results in future clinical trials, will maintain fast track designation or will receive regulatory approval. In addition, Anadys' results may be affected by risks related to competition from other biotechnology and pharmaceutical companies
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
2. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
3. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
9. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
10. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
11. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... DUBLIN , September 19, 2014 /PRNewswire/ ... and Markets ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced ... Cytogenetics Market 2014-2018" report to their ... ,Molecular Cytogenetics involves the study of chromosomes ... and functions of genes and chromosomes. It ...
(Date:9/18/2014)... 2014  LABSCO, the leading specialty sales ... to hospitals, physician office laboratories and alternate ... agreement with Sysmex America.  This agreement is ... the Sysmex XS-1000 i ™, Sysmex pocH-100 ... Automated Hematology Analyzers. The agreement ...
(Date:9/18/2014)... -- According to the new research ... Warming & Cooling), Application (Acute & Perioperative Care, ... & Paramedical Staff) - Global Forecasts & Trends ... global Temperature Management Market over the forecast period ... to reach $2.5 Billion by 2019 at CAGR ...
Breaking Medicine Technology:Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3LABSCO Renews Sysmex Distributorship Agreement 2LABSCO Renews Sysmex Distributorship Agreement 3Temperature Management Market Worth $2.5 Billion by 2019 2Temperature Management Market Worth $2.5 Billion by 2019 3Temperature Management Market Worth $2.5 Billion by 2019 4
... approved Makena (hydroxyprogesterone caproate) in February 2011 for the ... women who have had at least one prior preterm ... version of the active ingredient of Makena has been ... a pharmacist who compounded the drug.  In March 2011, ...
... Covance Inc. (NYSE: CVD ) today announced ... on Thursday, November 10, 2011 at 3:00 p.m. (ET).  Investors ... www.covance.com .  In order to register and download any necessary ... with headquarters in Princeton, New Jersey, is one of the ...
Cached Medicine Technology:FDA Statement on Makena 2Covance to Present at Credit Suisse 2011 Healthcare Conference 2
(Date:9/19/2014)... (PRWEB) September 19, 2014 Indiana Fiber ... Provider, announces the expansion of its Fiber Transport Services, ... in Chicago. By establishing a PoP at Cermak, ... Enterprise organizations looking for high bandwidth fiber transport service ... According to IFN Vice President of Sales and Marketing ...
(Date:9/19/2014)... California (PRWEB) September 19, 2014 Final Cut ... the production of the Float Theme template for Apple's ... and a simplistic template that allows FCPX users to create ... X," said Christina Austin, CEO of Pixel Film Studios, "With ... of the environment with the Float Theme." , Float ...
(Date:9/19/2014)... Getting together with friends is a big part of ... the desire to look graceful without spending a large sum ... range of fashionable prom dresses. Apart from this, it has ... the world. Now, all the global consumers can enjoy a ... its website. , The company’s chief executive officer says, ...
(Date:9/18/2014)... 2014 Defendants in more than ... pending in Pennsylvania’s Philadelphia Court of Common Pleas ... behalf of out-of-state plaintiffs dismissed, Bernstein Liebhard LLP ... the defendants maintain that circumstances surrounding the alleged ... have no connection to Pennsylvania. The filings did ...
(Date:9/18/2014)... 18, 2014 Memorial Cardiac and ... this week by performing the first ever, adult heart ... Network for Organ Sharing) approval to launch the adult ... only two programs in South Florida. , The ... Enrique Gongora, Medical Director of the Adult Heart ...
Breaking Medicine News(10 mins):Health News:Indiana Fiber Network Launches Point-Of-Presence in Chicago Data Center at Cermak 2Health News:Pixel Film Studios Releases Float Theme for Final Cut Pro X Users 2Health News:With New Semester Under Way, LunaDress Unveils The Most Fashionable Prom Dresses 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 2Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 4
... Pa., May 27 One of the nation,s,largest ... with Pennsylvania and 28 other states resolving claims ... said the agreement was reached with,Express Scripts Inc., ... million customers nationwide., As part of the ...
... pair of Los Alamos National Laboratory theorists have developed ... crisis managers determine in real time whether an emerging ... to spread globally. , In a paper published recently ... and Ruy Ribeiro of Los Alamos Theoretical Division describe ...
... Fair 2008 to Focus on Wellness,and Safety, ... released,today by the Montefiore Medical Center:, WHAT:, ... and younger, the themes for,this year,s Keeping Kids ... education, and safety and community. This FREE,fun-filled afternoon ...
... Family,Health International,s staff will make several key presentations ... publications at the annual,Global Health Council,s International Conference ... Washington, DC., Join FHI staff as they ... the recent violence in Kenya, community-based provision of,injectable ...
... distribution of mineral in arteries rather than amount ... of a person,s heart attack risk can be achieved ... only the amount, but also the distribution, of calcified ... , "Now we know that the location of the ...
... - Yale Universitys Christine Jacobs-Wagner has been ... Institute investigator, a non-profit medical research organization that ... Jacobs-Wagner, the Maxine Singer Associate Professor of Molecular, ... Yale scientists who now hold the prestigious appointment. ...
Cached Medicine News:Health News:Pennsylvania Attorney General Corbett Announces Multi-State Settlement With Express Scripts Inc. 2Health News:Pennsylvania Attorney General Corbett Announces Multi-State Settlement With Express Scripts Inc. 3Health News:Battling bird flu by the numbers 2Health News:Family Health International Featured at Global Health Council Conference 2Health News:Family Health International Featured at Global Health Council Conference 3Health News:Family Health International Featured at Global Health Council Conference 4Health News:New Calcium Measure Better Predictor of Heart Risks 2Health News:Jacobs-Wagner named Howard Hughes Investigator 2
... test device provides clear, reliable ... results can be determined in ... positive results require only 8 ... sample application will dependably and ...
AccuSign® DOA Series Opiates Test...
Accu-Stat Home Drug Test for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (mAMP), Opiates (OPI), and Phencyclidine (PCP)....
... ESR products, SEDIPLAST® is a completely ... to protect laboratory personnel from the ... is a uniquely designed erythrocyte sedimentation ... safety and convenience as well as ...
Medicine Products: